PMID- 35858498
OWN - NLM
STAT- MEDLINE
DCOM- 20221020
LR  - 20230119
IS  - 2211-0356 (Electronic)
IS  - 2211-0348 (Print)
IS  - 2211-0348 (Linking)
VI  - 66
DP  - 2022 Oct
TI  - Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 
      vaccination: A need for reconsideration?
PG  - 104035
LID - S2211-0348(22)00543-0 [pii]
LID - 10.1016/j.msard.2022.104035 [doi]
AB  - During the coronavirus disease 2019 (COVID-19) pandemic, mass vaccination was a 
      beneficial strategy in many countries. Nevertheless, reports of serious 
      complications such as postvaccination neuromyelitis optica spectrum disorder 
      (NMOSD) raised concerns about the safety of vaccines. Anamnart and colleagues 
      explained postvaccination NMOSD following different vaccines, including COVID-19. 
      To emphasize the message of this article, in this letter, we present a unique 
      case of postvaccination NMOSD with a fulminant and fatal course, which may show a 
      plausible relationship between COVID-19 vaccination and triggering 
      anti-aquaporin-4 antibody (AQP4-Ab).
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Motahharynia, Ali
AU  - Motahharynia A
AD  - Center for Translational Neuroscience, Isfahan University of Medical Sciences, 
      Isfahan, Iran; Isfahan Neuroscience Research Center, Isfahan University of 
      Medical Sciences, Isfahan, Iran.
FAU - Naghavi, Saba
AU  - Naghavi S
AD  - Center for Translational Neuroscience, Isfahan University of Medical Sciences, 
      Isfahan, Iran; Isfahan Neuroscience Research Center, Isfahan University of 
      Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, 
      Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Shaygannejad, Vahid
AU  - Shaygannejad V
AD  - Center for Translational Neuroscience, Isfahan University of Medical Sciences, 
      Isfahan, Iran; Isfahan Neuroscience Research Center, Isfahan University of 
      Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, 
      Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Adibi, Iman
AU  - Adibi I
AD  - Center for Translational Neuroscience, Isfahan University of Medical Sciences, 
      Isfahan, Iran; Isfahan Neuroscience Research Center, Isfahan University of 
      Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, 
      Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: 
      i_adibi@med.mui.ac.ir.
LA  - eng
PT  - Case Reports
PT  - Letter
DEP - 20220705
PL  - Netherlands
TA  - Mult Scler Relat Disord
JT  - Multiple sclerosis and related disorders
JID - 101580247
RN  - 0 (anti-aquaporin 4 autoantibody)
RN  - 0 (Aquaporin 4)
RN  - 0 (Autoantibodies)
RN  - 0 (COVID-19 Vaccines)
SB  - IM
CIN - Mult Scler Relat Disord. 2022 Dec;68:104089. PMID: 35987109
MH  - Humans
MH  - Aquaporin 4
MH  - Autoantibodies
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - *Neuromyelitis Optica/complications
MH  - Vaccination/adverse effects
PMC - PMC9254455
OTO - NOTNLM
OT  - COVID-19 vaccine
OT  - NMOSD
OT  - Neuromyelitis optica spectrum disorder
OT  - Postvaccination
COIS- Declaration of Interests The authors declare that they have no known competing 
      financial interests or personal relationships that could have appeared to 
      influence the work reported in this paper.
EDAT- 2022/07/21 06:00
MHDA- 2022/10/20 06:00
PMCR- 2022/07/05
CRDT- 2022/07/20 18:13
PHST- 2022/04/26 00:00 [received]
PHST- 2022/07/04 00:00 [accepted]
PHST- 2022/07/21 06:00 [pubmed]
PHST- 2022/10/20 06:00 [medline]
PHST- 2022/07/20 18:13 [entrez]
PHST- 2022/07/05 00:00 [pmc-release]
AID - S2211-0348(22)00543-0 [pii]
AID - 104035 [pii]
AID - 10.1016/j.msard.2022.104035 [doi]
PST - ppublish
SO  - Mult Scler Relat Disord. 2022 Oct;66:104035. doi: 10.1016/j.msard.2022.104035. 
      Epub 2022 Jul 5.